Assessment of the prognostic value of serum beta-2 microglobulin and transforming growth factor beta levels for multiple myeloma patients
DOI:
https://doi.org/10.60988/p.v37i2S.214Keywords:
plasma cell tumor; beta-2 microglobulin; transforming growth factor beta; multiple myeloma; IraqAbstract
This study has evaluated the joint prognostic utility of circulating beta-2 microglobulin (β2-microglobulin) and transforming growth factor beta (TGF-β) levels in 98 patients with multiple myeloma (MM) and 31 healthy volunteers (controls). Participants were recruited from the Haematology Department of the Marjan Medical Hospital, Babil Province, Iraq, between March 2021 and December 2022. The combined biomarker model yielded an overall diagnostic accuracy of 0.862, with a sensitivity of 93.2% and specificity of 90.1% for distinguishing MM cases from healthy individuals. Notably, β2-microglobulin alone achieved an area under the curve (AUC) of 0.961 in differentiating stage III from stage II MM. These findings support the potential of integrated β2-microglobulin and TGF-β profiling to enhance diagnostic and staging precision in MM, warranting further investigation into their clinical and translational applicability.
References
1. Mousa M.J., Al-Hindy H.A.A., Al-Mumin A.S. Evaluation of serum cystatin C levels in multiple myeloma: diagnostic significance and clinical implications. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(s2), 145–148, 2024. DOI: 10.61873/HHPT2430
2. Elbezanti W.O., Challagundla K.B., Jonnalagadda S.C., Budak-Alpdogan T., Pandey M.K. Past, present, and a glance into the future of multiple myeloma treatment. Pharmaceuticals (Basel) 16(3), 415, 2023. DOI: 10.3390/ph16030415
3. Ștefan G., Cinca S., Chiriac C., Zugravu A., Stancu S. Multiple myeloma and kidney impairment at diagnosis: a nephrological perspective from an Eastern European country. Medicina (Kaunas) 59(7), 1326, 2023. DOI: 10.3390/medicina59071326
4. Abed I.N., Al-Timari U.S., Al-Hussein Hassan H.A., Dwayyikh A.T. Correlation between neutrophil gelatinase associated with lipocaline and beta-2 microglobulin with other renal markers in Iraqi patients with multiple myeloma. J. Tech. 4(s), 101–104, 2022. DOI: 10.51173/jt.v4i33.679
5. Ramadan G.M., Al-Hindy H.A.A.M., Mousa M.J., Al-Sadi H.I. Evaluation of transforming growth factor-beta 1 (TGFβ1) levels in cases with multiple myeloma: case-control study among Iraqis. J. ReAtt. Ther. Dev. Divers. 5(2s), 516–523, 2022.
6. Lin G., Hari P., Chhabra S., Hamadani M., D’Souza A., Szabo A., et al. The significance of beta-II microglobulin (β2M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI). J. Clin. Oncol. 38(15s), 8544, 2020. DOI: 10.1200/JCO.2020.38.15_suppl.8544
7. Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L., et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33(26), 2863–2869, 2015. DOI: 10.1200/JCO.2015.61.2267
8. Xue H.Y., Wei F. TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-β in the microenvironment of multiple myeloma. Ann. Hematol. 103(11), 4351–4362, 2024. DOI: 10.1007/s00277-024-05843-4
9. de Carvalho F., Colleoni G.W., Almeida M.S., Carvalho A.L., Vettore A.L. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int. J. Cancer 125(8), 1985–1991, 2009. DOI: 10.1002/ijc.24431
10. Yeung J., Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J. Clin. Pathol. 61(7), 832–836, 2008. DOI: 10.1136/jcp.2007.049585
